Breast Cancer: Ipatasertib + Tecentriq + Paclitaxel

Breast Cancer: Ipatasertib + Tecentriq + Paclitaxel

​Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee B-66 Travel Service Provider License No. 35, Fukuoka Prefecture, Japan ​​Medical Device Sales and Lease Management, Japan

Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee B-66 Travel Service Provider License No. 35, Fukuoka Prefecture, Japan ​​Medical Device Sales and Lease Management, Japan

​ (Breast Cancer) Ipatasertib + Tecentriq + Paclitaxel

Ipatasertib + Tecentriq + chemotherapy as first-line treatment for triple-negative breast cancer achieves an objective response rate of 73%, unaffected by PD-L1 status and genetic factors.

On April 1, 2019, Roche announced Phase I clinical trial results for oral AKT inhibitor Ipatasertib + Tecentriq + chemotherapy (paclitaxel) at the American Association for Cancer Research conference (AACR 2019).

For previously untreated patients with locally advanced or metastatic triple-negative breast cancer, this study assessed the safety and efficacy of this therapeutic combination. The response rate was unaffected by PD-L1 status, PI3KCA/AKT1/PTEN gene mutations.

Additionally, the most common adverse effects observed in most patients were: diarrhea at 19%, and skin itching and desquamation at 27%.

Based on Phase I clinical trial results, this therapeutic approach demonstrated an objective response rate of 73% in triple-negative breast cancer, showing promising efficacy.

Data Source: https://www.roche.com/media/releases/med-cor-2019-04-01.htm

https://www.roche.com/media/releases/med-cor-2019-04-01.htm

Copyright© 2015 Shingihou Co., Ltd. All rights reserved.

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5